These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31292254)

  • 1. The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain.
    Schmidt SH; Knape MJ; Boassa D; Mumdey N; Kornev AP; Ellisman MH; Taylor SS; Herberg FW
    Proc Natl Acad Sci U S A; 2019 Jul; 116(30):14979-14988. PubMed ID: 31292254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach.
    Agrahari AK; Doss GPC; Siva R; Magesh R; Zayed H
    J Theor Biol; 2019 May; 469():163-171. PubMed ID: 30844370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G2385R and I2020T Mutations Increase LRRK2 GTPase Activity.
    Ho DH; Jang J; Joe EH; Son I; Seo H; Seol W
    Biomed Res Int; 2016; 2016():7917128. PubMed ID: 27314038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.
    Guaitoli G; Raimondi F; Gilsbach BK; Gómez-Llorente Y; Deyaert E; Renzi F; Li X; Schaffner A; Jagtap PK; Boldt K; von Zweydorf F; Gotthardt K; Lorimer DD; Yue Z; Burgin A; Janjic N; Sattler M; Versées W; Ueffing M; Ubarretxena-Belandia I; Kortholt A; Gloeckner CJ
    Proc Natl Acad Sci U S A; 2016 Jul; 113(30):E4357-66. PubMed ID: 27357661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2.
    Schmidt SH; Weng JH; Aoto PC; Boassa D; Mathea S; Silletti S; Hu J; Wallbott M; Komives EA; Knapp S; Herberg FW; Taylor SS
    Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34088839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural analysis of the full-length human LRRK2.
    Myasnikov A; Zhu H; Hixson P; Xie B; Yu K; Pitre A; Peng J; Sun J
    Cell; 2021 Jun; 184(13):3519-3527.e10. PubMed ID: 34107286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Modeling Study on the Interaction Mechanism between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling.
    Tan S; Zhang Q; Wang J; Gao P; Xie G; Liu H; Yao X
    ACS Chem Neurosci; 2022 Mar; 13(5):599-612. PubMed ID: 35188741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease.
    Naskar A; Roy RK; Srivastava D; Patra N
    J Phys Chem B; 2024 Jul; 128(28):6657-6669. PubMed ID: 38822803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
    Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
    Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics.
    Wu CX; Liao J; Park Y; Reed X; Engel VA; Hoang NC; Takagi Y; Johnson SM; Wang M; Federici M; Nichols RJ; Sanishvili R; Cookson MR; Hoang QQ
    J Biol Chem; 2019 Apr; 294(15):5907-5913. PubMed ID: 30796162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
    Nagarajan N; Chellam J; Kannan RR
    J Cell Biochem; 2018 Jun; 119(6):4878-4889. PubMed ID: 29369408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
    Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
    J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markov State Models and Molecular Dynamics Simulations Provide Understanding of the Nucleotide-Dependent Dimerization-Based Activation of LRRK2 ROC Domain.
    Li X; Qi Z; Ni D; Lu S; Chen L; Chen X
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression.
    Zhu Y; Wang C; Yu M; Cui J; Liu L; Xu Z
    Protein Cell; 2013 Sep; 4(9):711-21. PubMed ID: 27023913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.